Home / Market News / $ALNY
fiscal.ai Corporate Catalyst Impact 75/100 ● positive

Alnylam-Licensed Elebsiran Shows Positive Results in Phase 3 ECLIPSE 1 Trial for Hepatitis Delta

Nov 9, 2026, 2:03 AM UTC · Primary ticker $ALNY

The filing announces positive Phase 3 trial results for Elebsiran, an Alnylam-licensed drug for Hepatitis Delta, meeting all primary endpoints. This significantly de-risks the drug's path to market and provides a strong positive signal for Alnylam and its licensee.

Alnylam Pharmaceuticals announced that its licensed investigational siRNA, Elebsiran, achieved all primary endpoints in the Phase 3 ECLIPSE 1 trial for Hepatitis Delta. This is a significant positive development as it validates the drug's efficacy and safety profile, with 100% virologic response at Week 24 and 79% undetectable virus levels by Week 48. For Alnylam, this de-risks a key pipeline asset and strengthens its licensing strategy, potentially leading to future royalty streams or milestone payments. The positive results pave the way for a global regulatory filing package planned for mid-2027, indicating a clear path towards commercialization. Traders should see this as a long-term positive for Alnylam, with potential for stock appreciation as the drug progresses through regulatory approval and eventual market launch.

$ALNY positive Licensed drug shows strong Phase 3 results
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.